A Closer Look: China’s Pharmaceutical Bribery Scandal Continues To Spread
This article was originally published in PharmAsia News
Executive Summary
Sanofi is the latest company to feel the heat after an anonymous whistleblower alleged that Chinese employees bribed doctors to prescribe Avapro and Avalide. PharmAsia News takes a closer look at the latest developments in a fast-moving scandal that has engulfed GSK and now threatens others.
You may also be interested in...
AstraZeneca’s Plan To Spur Brilinta Sales Is On Track, CEO Says
Plans to jumpstart growth of Brilinta are working, AstraZeneca said during the company’s second quarter sales and earnings call Aug. 1. Investors may not see the results until the end of the year, however.
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.